Equinor ASA (EQNR)

Stockholders Equity

$43.06B

Quarterly · Period ending: · USD

EQNR logo

EQNR Stockholders Equity

Latest reported$43.06B
EQNR Quarterly Shareholders Equity ($4.82B → $43.06B)
High-resolution chart · PNG

EQNR stockholders equity history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Equinor ASA Stockholders Equity — Quarterly (USD)
Period endingStockholders Equity (USD)
43,063,000,000
43,571,000,000
40,424,417,000
40,524,992,000
41,922,205,000
45,820,000,000
42,342,000,000
44,352,000,000
43,671,000,000
50,067,000,000
48,490,000,000
48,718,000,000
49,719,000,000
57,165,000,000
53,988,000,000
42,706,000,000
41,206,000,000
43,233,000,000
39,010,000,000
37,018,000,000
37,023,000,000
35,764,000,000
33,873,000,000
34,084,000,000
35,587,000,000
36,327,000,000
41,139,000,000
40,983,000,000
45,013,000,000
45,098,000,000
42,970,000,000
41,907,000,000
41,019,000,000
42,590,000,000
39,861,000,000
38,204,000,000
37,882,000,000
36,618,000,000
35,072,000,000
40,050,000,000
40,200,000,000
42,162,000,000
40,350,653,664
42,161,381,448
44,924,223,741
45,037,123,510
51,218,386,970
56,703,677,904
59,605,737,806
62,441,201,202
58,454,819,603
56,496,516,824
54,018,467,007
57,477,254,282
57,174,073,463
53,725,819,049
50,845,728,742
50,319,661,322
46,728,990,751
43,831,762,336
43,875,401,489
41,108,862,663
37,344,060,963
35,721,046,247
31,566,739,276
35,615,946,506
34,222,728,410
33,008,849,097
29,371,059,797
31,425,029,691
30,763,000,000
33,882,000,000
35,386,000,000
37,151,000,000
32,636,000,000
23,157,000,000
20,291,000,000
21,512,000,000
19,605,000,000
17,810,000,000
16,853,000,000
17,620,000,000
15,794,000,000
14,640,000,000
13,393,000,000
14,624,000,000
14,089,000,000
11,659,000,000
10,634,000,000
10,954,000,000
10,554,000,000
9,469,000,000
8,678,000,000
8,693,000,000
8,210,000,000
7,192,000,000
6,788,000,000
6,072,000,000
5,762,000,000
5,504,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.